The Promising Effect of Tocilizumab on Chronic Antibody-Mediated Rejection (cAMR) of Kidney Transplant

Five clinical trials, 105 patients. Mean eGFR loss -0.141 mL/min/1.73m2 (95% CI -0.409 to 0.126; p=0.298) and DSA reduction -0.266 MFI (95% CI -0.861 to 0.329; p=0.377) — both statistically NON-significant, heterogeneity I2 = 0.00%. Concludes large randomised trials comparing standard cAMR management with tocilizumab are still needed.